{
    "SPADE_N_14930": {
        "Sequence Information": {
            "Peptide Name": "Bisebromoamide",
            "Sequence": "AXXCLXX",
            "Sequence Length": 7,
            "Biological Activity": [
                "Anticancer"
            ],
            "Binding Target": "1. Lipid Bilayer",
            "Source": "1. Lyngbya sp.",
            "Gene": "",
            "PDB ID": "",
            "UniProt Entry": [],
            "Literature": [
                {
                    "Title": "Bisebromoamide, a potent cytotoxic peptide from the marine cyanobacterium Lyngbya sp.: isolation, stereostructure, and biological activity.",
                    "Pubmed ID": "19803465",
                    "Reference": "Org Lett. 2009;11:5062-5065",
                    "Author": "Teruya T, Sasaki H, Fukazawa H, Suenaga K",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/19803465"
                }
            ],
            "SPADE ID": "SPADE_N_14930",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_00250",
                    "Similarity": 1.0,
                    "Sequence": "RTCESQSHRFKGACLSDTNCASVCQTEGFPAGDCKGARRRCFCVKPC"
                },
                {
                    "SPADE_ID": "SPADE_N_00390",
                    "Similarity": 1.0,
                    "Sequence": "KSTCKAESNTFPGLCITKPPCRKACLSEKFTDGKCSKILRRCICYKPCVFDGKMIQTGAENLAEEAETLAAALLEEEMMDN"
                },
                {
                    "SPADE_ID": "SPADE_N_00436",
                    "Similarity": 1.0,
                    "Sequence": "EDRSKLIPIGPCSKIANCNQTCIESQFLGGKCIKWYPDSIKETCACLVKPSITHV"
                }
            ],
            "Hemolytic Activity": "",
            "Target Organism": "Human breast adenocarcinoma MCF-7(IC50=0.035µM),Human breast adenocarcinoma MDA-MB-231(IC50=0.038µM),Human breast carcinoma BSY-1(IC50=0.024µM),Human breast carcinoma HBC-4(IC50=0.097µM),Human glioblastoma U251-MG(IC50=0.034µM),Human Astrocytoma SF-268(IC50=0.038µM),Human Astrocytoma SF-539(IC50=0.028µM),Human brain cancer SNB-78(IC50=0.036µM),Human colon adenocarcinoma HT29(IC50=0.033µM),Human colon adenocarcinoma HCT-15(IC50=0.1µM),Human colon adenocarcinoma HCT 116(IC50=0.093µM),Human lung adenocarcinoma NCI-H23(IC50=0.092µM),Human lung adenocarcinoma NCI-H522(IC50=0.027µM),Human lung carcinoma NCI-H460(IC50=0.035µM),Human lung carcinoma A549(IC50=0.039µM),Human lung carcinoma DMS 273(IC50=0.037µM),Human melanoma LOX-IMVI(IC50=0.026µM),Human epithelial carcinoma OVCAR-3(IC50=0.028µM),Human epithelial carcinoma OVCAR-5(IC50=0.1µM),Human ovarian adenocarcinoma SK-OV-3(IC50=0.086µM),Human renal adenocarcinoma ACHN(IC50=0.032µM),Human gastric cancer MKN 45(IC50=0.037µM),Human gastric cancer MKN 28(IC50=0.047µM),Human gastric cancer MKN 7(IC50=0.013µM),Human prostate cancer DU145(IC50=0.061µM),Human prostate adenocarcinoma PC-3(IC50=0.1µM)"
        }
    }
}